Engineers, doctors and scientists at UCLA and Rutgers University have developed a tool that measures the physical strength of individual cells 100 times faster than current technologies.
The new device could make it easier and faster to test and evaluate new drugs for diseases associated with abnormal levels of cell strength, including hypertension, asthma and muscular dystrophy.
It is the first tool that can measure the strength of thousands of individual cells at a time. The study’s co-author, Dr. Reynold A. Panettieri Jr, said: ‘We took a fresh approach to identify molecules that could serve as drugs to meet an unmet need for new treatments to treat or cure chronic disease.’
‘Our new experimental platforms are capable of screening millions of molecules to identify the best drug candidates for the right patients.’
‘The system leverages the state of the art bioengineering techniques and use of human cells derived from patients with chronic diseases that offers greater likelihood of predicting therapeutic responses.’
Cells use physical force for essential biological functions – both as individual cells, for example in cell division or immune function, and as large groups of cells in tissue, for example, when muscles contract.
Disruptions in a cell’s ability to control the levels of force they exert can lead to diseases or loss of important bodily functions. For example, asthma is caused by the smooth muscle cells that line the airways squeezing more than normal. And abnormally weak cell forces are associated with heart failure, muscular dystrophy and migraine headaches.
The device is called fluorescently labeled elastomeric contractible surfaces, or FLECS. Its key component is a flexible rectangular plate with more than 100,000 uniformly spaced X-shaped micropatterns of proteins that are sticky so cells settle on and attach to them.
‘Our platform can markedly improve the speed and fidelity of screening of millions of potential molecules in order to find new candidates that can rapidly progress through the approval process to become new drugs in asthma, cancer and heart disease,’ Panettieri said.
To test the tool, the researchers analyzed drugs that make cells either contract or relax, using human smooth muscle cells that line airways in the body. The researchers compared the results of those tests to what was already known about how lung tissue reacts to the drugs and found that FLECS captured the same types of reactions, only more precisely because it could analyse the reactions in cell-by-cell detail.
They also tested the force of macrophages, cells in the immune system that rid the body of potentially harmful particles, bacteria and dead cells. They found that when a typical macrophage receives a signal that an infection is present, it can exert force approximately 200,000 times its own weight in water. But some macrophages were more than three times stronger than that.
The researchers also used FLECS to analyze cell force and then compared the results of that test to a current standard test, which judges cell force by analysing the amount of calcium in the cells. They were surprised that the results of the calcium test did not correlate well with how much cells contracted. The finding suggests that the calcium test may be limited, because, unlike that tes, FLECS looks at a level of detail down to an individual cell.
The UCLA researchers found that individuals cells from people who had died from severe asthma contract with more force, both generally and during an asthma attack, than they do in healthy people.